Back to CVE records
High 8.1Published Apr 2, 2026

CVE-2026-5246A vulnerability was determined in Cesanta Mongoose up to 7.20.

Updated under an hour ago ()

Does this affect you?

It affects cesanta mongoose. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

A vulnerability was determined in Cesanta Mongoose up to 7.20. Affected is the function mg_tls_verify_cert_signature of the file mongoose.c of the component P-384 Public Key Handler. Executing a manipulation can lead to authorization bypass. The attack can be executed remotely. Attacks of this nature are highly complex. The exploitability is told to be difficult. The exploit has been publicly disclosed and may be utilized. Upgrading to version 7.21 is able to address this issue. This patch is called 0d882f1b43ff2308b7486a56a9d60cd6dba8a3f1. The affected component should be upgraded. The vendor was contacted early, responded in a very professional manner and quickly released a fixed version of the affected product.

CVSS
8.1 HIGH (v3.1, NVD)CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-285, CWE-639
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Analyzed
Record last updated
Jun 17, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
cesanta mongoose
cesanta:mongoose
from 7.0 before 7.21
NVD

References

  • product
  • patch
  • product, release-notes
  • third-party-advisory, vdb-entry
  • third-party-advisory, vdb-entry
  • permissions-required, vdb-entry

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.